Web(r)-2-(1-(6-Amino-5-chloropyrimidine-4-carboxamido)ethyl)-n-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide C17H12Cl2F3N7O2S CID … WebFeb 10, 2024 · DAY101 is designed as a first-in-class, oral, brain-penetrant, highly selective type II pan-RAF kinase inhibitor. The Company has initiated the pivotal Phase 2 FIREFLY-1 study with DAY101 in...
A Study to Evaluate DAY101 in Pediatric and Young Adult …
WebJul 27, 2024 · DAY101 is a type II RAF inhibitor found to selectively inhibit both monomeric and dimeric RAF kinase, which may broaden its potential clinical application to treat an … WebFeb 3, 2024 · Overview. FIREFLY-1 is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma or an advanced solid tumor harboring a known BRAF alteration. Full Title of Study: “FIREFLY-1: A Phase 2, Open ... branding recommendations
PNOC029: Nivolumab and DAY101 for the treatment of newly …
WebAug 17, 2024 · SOUTH SAN FRANCISCO, Calif., Aug. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing... WebThe effects of DAY101 and nivolumab on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate … WebNov 9, 2024 · These phase 1 data provide initial pharmacokinetic parameters outlining oral weekly dosing of DAY101 in pediatric patients with radiographically recurrent and progressive LGG. Plasma exposures of DAY101 are similar in children and adults. Oral weekly DAY101 is well-tolerated and shows anti-tumor activity. branding references